Loratadine

CHEMBL998 Phase 4 Disetujui Small molecule

Half-Life

8 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

382.9 g/mol

LogP

5.2

Phase

4

A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

Berat Molekul

382,8800 g/mol

LogP

5,20

TPSA

42,40 Å²

Lipinski RO5

Lulus

Area Terapeutik

Rheumatoid Arthritis Asthma Parkinson's Disease Psoriasis Multiple Sclerosis Chronic Kidney Disease Lymphoma Breast Cancer Atopic Dermatitis Leukemia

Kelas Obat

R — R - Respiratory System

Mekanisme Kerja

Second-generation H1 antihistamine with minimal CNS effects.

Pharmacokinetics (PK)

Half-Life 8 hours

Pharmacodynamics (PD)

Mekanisme

Second-generation H1 antihistamine with minimal CNS effects.

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

InChI

InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

Molecular Formula

C22H23ClN2O2

HBD / HBA

- / 3

Ikatan yang Dapat Dirotasi

2

Atom Berat

27

HRH1 (Histamine H1 Receptor) Antagonist

Primary Target

Minor Loratadine + Fluconazole

Fluconazole inhibits CYP3A4-mediated metabolism of loratadine, modestly increasing loratadine plasma concentrations; however, loratadine's poor CNS penetration limits the clinical consequence.

Minor Loratadine + Azithromycin

Azithromycin is a weak CYP3A4 inhibitor that can modestly raise loratadine plasma levels; the clinical impact is minimal given loratadine's wide therapeutic index and low cardiac risk.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

Second-generation H1 antihistamine with minimal CNS effects.

Key pharmacokinetic parameters for Loratadine: Half-life: 8 hours.

Yes, Loratadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

Same Drug Class

Albuterol Small molecule Montelukast Small molecule Cetirizine Small molecule Diphenhydramine Small molecule

Same Target

Escitalopram Small molecule Cetirizine Small molecule Diphenhydramine Small molecule Trazodone Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL998. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3957. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Loratadine di PillFYI

Struktur

Data Cepat

Class: R - Respiratory System
Rumus: C22H23ClN2O2
Sinonim: 5

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Loratadine

Area Terapeutik

Kelas Obat

Mekanisme Kerja

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

Cite this structure

Embed this structure

No side effects recorded

Pertanyaan yang Sering Diajukan

Related Drugs

Same Drug Class

Same Target

References & Data Sources

Embed This Widget